Current Edition


Annual report highlights the Group’s progress and commitments to our
people, our planet, and the communities in which we operate_

Almac Group today announces the release [1] of the company’s 2023
Corporate Social Responsibility report, which highlights Almac’s
progress and commitments to our people, our planet, and the communities
in which we operate.

The report also provides insights into Almac’s client delivery across
the drug development pipeline, and a look into the company’s ambitious
growth strategy posed to sustain best-in-class service offerings to
clients and bolster innovation.

Alan Armstrong, Chairman and CEO, commented: “Almac’s mission to
advance human health is the driving force behind everything we do as an
organisation. We are exceedingly proud of how we have delivered on our
responsibilities this year—particularly, our progress towards our
commitment to reach net zero by 2045, our further investment in health
and wellbeing offerings for our people, and our contributions to our

“We are also proud to recognise the essential role our colleagues have
played in our success – by living out our mission each day, they are
collectively impacting human health across the globe.”

In 2022, Almac announced [2] a commitment to reach net zero by 2045, and
to reduce Scope 1 and Scope 2 emissions by 50 percent by 2030.
Highlights from this year’s report that support the company’s net
zero ambition include:

* Joining the Science Based Targets Initiative (SBTi) [3], which
defines and promotes best practice in science-based target setting for
the reduction of greenhouse gases
* Appointing [4] a dedicated Global Energy Manager to drive actions to
support Almac’s net zero commitment, and develop business improvement
initiatives across the globe

Almac is also wholly committed to supporting, developing, and rewarding
our people, as well as making a positive and lasting contribution to our
communities. Highlights from the last year in these areas include:

* 2,000 employees received recognition awards
* Reaching 100% of employees with health and wellbeing programmes
* Supporting 40 different charities through global philanthropy
* Reaching an estimated 10,000 post-primary pupils through in-person
and virtual outreach programmes

Almac’s CSR strategy is designed to align priorities with the United
Nations’ Sustainable Development Goals (SDGs) and the Pharmaceutical
Supply Chain Initiative (PSCI).

Read the full report here – [5]

About Almac Group

The Almac Group is an established contract development and manufacturing
organisation providing an extensive range of integrated services across
the drug development lifecycle to the pharmaceutical and biotech sectors
globally. Its innovative services range from R&D, biomarker discovery
development and commercialisation, API manufacture, analytical services,
formulation development, clinical trial supply, IRT (IVRS/IWRS) through
to commercial-scale manufacture.

The international company is a privately owned organisation which has
grown organically, now employing 7,000 highly skilled personnel across
18 facilities including Europe, the USA and Asia.

To keep up to date with latest news, follow us on Twitter [6] and
LinkedIn [7] or visit [8].